spacer
home > > spring 2004 > the keys to r&d: the rise of enterprise asset management in the pharma industry
PUBLICATIONS


The Keys to R&D: The Rise of Enterprise Asset Management in the Pharma Industry

The pharmaceutical industry has proven to be a somewhat fortunate anomaly over the past few years. To its left and its right - in the financial sector, the manufacturing sector and the technology sector - an increasingly demoralising war has been waged against costs. Looking to every corner of infrastructure and operations, the world seemed to hinge on streamlining processes and fighting to gain an edge that would enable another quarter of survival, however fiscally static.

For many pharma companies, however the success of science and investors' faith in new blockbuster products has set a different stage. The focus on research, development and riding new drugs across successful European distribution and into the sunset of FDA approval was full steam ahead. The 'back office' was a non-factor, just as it was for financial companies of the 1990s. Inefficient processes may have caused muted losses, but the temporary setbacks of revamping operations were too daunting for wholesale changes to warrant much consideration.

As a result, the pharma industry finds itself in jeopardy of falling prey to the same scramble necessitated when responding to market-dictated cost pressure experienced in those other industries. Pharma's R&D and marketing approaches are languishing in the past, working off procedures that were brilliant a decade ago, but are now slowly being rendered ineffective. There is a general reluctance among pharma companies to view the end-user (the patient) as a customer, and instead they look directly to doctors and health care organisations - just as they did 10 years ago.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Lorenzo Nanetti, Business Development Manager of Pharmaceuticals at BearingPoint, Switzerland and Michael J Desabris, Senior Manager, Enterprise Asset Management at BearingPoint, USA

Lorenzo Nanetti is a Business Development Manager with BearingPoint's pharmaceuticals segment, bringing to BearingPoint's clients 15 years of experience in delivering solutions to the pharmaceutical industry. Lorenzo has worked across disparate cultures and management teams to implement creative solutions that leverage his knowledge of critical success factors for drug research, drug development and marketing, in relation to changes within the pharmaceutical industry.

Michael J Desabris has over 20 years' experience as a business advisor and system integrator in the pharmaceutical and FDA regulated industries. He has built enduring relationships with clients by helping them improve or create new enterprise business models and innovative solutions, enabling organisations to leverage change and meet new business challenges. From business strategy to implementation, Michael has combined industry best practices, solutions and experiences to rapidly deliver results and returns on investment throughout the entire facilities and asset life cycle from strategic planning, design, construction, commissioning, start-up and occupancy, to renovation and decommissioning.

spacer
Lorenzo Nanetti
spacer
spacer
spacer
Michael J Desabris
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Byondis’ Investigational Antibody-Drug Conjugate SYD985 Selected for I-SPY 2 TRIAL™ in Early-Stage Breast Cancer

Byondis B.V. (formerly Synthon Biopharmaceuticals) today announced that Quantum Leap Healthcare Collaborative™ (Quantum Leap) selected the company’s investigational antibody-drug conjugate (ADC) SYD985 ([vic-]trastuzumab duocarmazine) for a new investigational treatment arm in its ongoing I-SPY 2 TRIAL™ for neoadjuvant treatment of locally advanced breast cancer.
More info >>

White Papers

Microalgae Culture Using the DASGIP® PBR4 Module for Illumination with a New Brunswick™ CelliGen® 310 Stirred-tank Bioreactor

Eppendorf

The number of bioprocess applications for microalgae has increased in recent years, particularly in the fi eld of biofuel production. The combination of the New Brunswick CelliGen 310 stirred-tank bioreactor and the DASGIP LED Illumination System creates a bioreactor setup which is capable of supporting high density microalgal growth. Using the stand-alone Eppendorf DASGIP PBR4 Module, LED illumination spectra and intensities can be controlled for optimal support of all types of chlorophylls and carotenoids. For this study in which high density culture of up to 1.5 x 107 cells/mL was achieved, the unicellular freshwater alga, Dunaliella tertiolecta, was used.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement